D-Cycloserine for Serine Palmitoyltransferase Inhibition

Completed · Phase 4

Conditions studied: Hereditary Spastic Paraplegia

In brief

The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia

Key facts

Study ID

NCT07542548

Run by

Massachusetts General Hospital

People needed

1

Starts

2024-07-10

Expected to finish

2026-03-17

Last updated by the study team

2026-04-21

Who can join

Age: 6 and older, up to 6. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• • Informed consent provided by the participant's parents.
• Ability to travel to the study and assessment sites (Massachusetts General Hospital Main Campus, 55 Fruit St, Boston, MA 02114 and MGH IHP Impact Practice Center, 2 Constitution Wharf, Charlestown, MA 02129) and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records.
• Clinical phenotype, neuroimaging, genetic testing and biochemical results consistent with a diagnosis of SPTSSA-related Complex Hereditary Spastic Paraplegia

You may not qualify if…

• • Participant has any known contraindication to or unwillingness to undergo procedures listed in the protocol
• Use of investigational medication within 5 half-lives of the drug at enrollment
• Participant has any condition that, in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.